References
- Bolden-Watson C., Richelson E. Blockade by newly developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sciences 1993; 52: 1023–1029
- Boyer W.F. Potential indications for the selective serotonin reuptake inhibitors. International Clinical Psychopharmacology 1992; 6(suppl. 5)5–12
- Burke M.J., Preskorn S.H. Short Term Treatment of Affective Disorders with Standard Antidepressants. Psychopharmacology: The Fourth Generation of Progress, F. Bloom, D. Kupfer. Raven Press, New York 1995; 1053–66
- Cusack B., Nelson A., Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berlin) 1994; 114: 558–565
- Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology (Berlin) 1986; 90: 131–138
- Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multi-center study. Journal of Affective Disorders 1990; 18: 289–299
- Dunner D.L., Dunbar G.C. Optimal dose regimen for paroxetine. Journal of Clinical Psychiatry 1992; 53(2)21–26, suppl
- Eison A.S., Eison M.S., Torrente J.R., Wright R.N., Yocca F.D. Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharmacology 1990; 26: 311–315
- Fabre L.F., Abussahab F.S., Amin M., et al. Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biological Psychiatry
- Food and Drug Administration (1993a) . WashingtonPsychopharmacology Advisory Committee Meeting on Venlafaxine, DC, April, 1993
- Food and Drug Administration (1993b) . Psychopharmacology Advisory Committee Meeting on Nefazodone, Washington, DC, July, 15–181993
- Feighner J.P. The role of venlafaxine in rational antidepressant therapy. Journal of Clinical Psychiatry 1994; 55(9)62–68, suppl A
- Hendrickse W.A., Roffwarg H.P., Gran-Nemann B.D., Orsulak P.J., Armitage R., Cain J.W., Battaglia J., Debus J.R., Rush A.J. The effects of fluoxetine on the polysom-nogram of depressed outpatients: a pilot study. Neuropsychopharmacology 1994; 10: 85–91
- Lane R., Baldwin D., Preskorn S.H. The SSRIs: advantages, disadvantages and differences. Journal of Psychopharmacology 1994, in press
- Lemberger L., Bergstrom R.F., Wolen R.L., Farid N.A., Enias G.G., Aronoff A.R. Fluoxetine: clinical pharmacology and physiologic disposition. Journal of Clinical Psychiatry 1985; 46: 14–19
- Marsden C.A., et al. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT inhibitor. Psychopharmacology 1987; 1: 244–250
- Physician's Desk Reference. Medical Economics Data Production Co., Montvale, NJ 1994
- Preskorn S.H. The future and psychopharmacology: Needs and potentials. Psychiatric Annals 1990; 20: 625–633
- Preskorn S.H. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. Journal of Clinical Psychiatry 1993; 54(9)3–7, suppl
- Preskorn S.H. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline. International Clinical Psychopharmacology 1994a; 9(suppl. 3)13–19
- Preskorn S. Antidepressant drug selection: Criteria and options. Journal of Clinical Psychiatry 1994b; 55(9)6–24, suppl. A
- Preskorn S.H. Beyond DSM-IV: What is the cart and what is die horse?. Psychiatric Annals 1994c, in press
- Preskorn S.H. Comparison of the tolerability of nefazodone, imipramine, fluoxetine, sertraline, paroxetine, and venlafaxine. Journal of Clinical Psychiatry 1995; 55, suppl
- Preskorn S.H., Fast G.A. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. Journal of Clinical Psychiatry 1991; 52: 23–33
- Preskorn S., Lacey R. Polypharmacy: When is it rational?. Journal of Practical Psychiatry and Behavioral Health 1995, in press
- Preskorn S., Lane R. Fifty milligrams of sertraline as the optimum dose. Clinical Pharmacokinetics 1995, in press
- Wernicke J.F., Dunlop S.R., Dornseif B.E., Bosomworth J.C., Hamber M. Low dose fluoxetine therapy for depression. Psychopharmacology Bulletin 1988; 24: 183–188
- Wernicke J.F., Dunlop S.R., Dornseif B.E., Zerbe R.L. Fixed dose fluoxetine therapy for depression. Psychopharmacology Bulletin 1987; 23: 164–168